News Releases

LYNBROOK, N.Y., Sept. 5, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX^® in the U.S. and Xiapex^® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the following upcoming conferences.

• Rodman & Renshaw 19th Annual Global Investment Conference at 11:40 a.m. on Tuesday, September 12, 2017 in New York, NY. Link: http://wsw.com/webcast/rrshq27/bstc
• 2017 Cantor Fitzgerald Global Healthcare Conference at 1:05 p.m. ET on Wednesday, September 27, 2017 in New York, NY. Link: http://wsw.com/webcast/cantor6/bstc

A live audio webcast of each presentation can also be accessed under the "Events and Presentation" tab in the Investors section of the Company's website at www.biospecifics.com. An archived replay of the webcast will be available for 30 days after the live event concludes.

About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX^® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX^® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Europe and Australia. Endo is partnered with Sobi, Actelion and Asahi Kasei for Dupuytren's contracture and Peyronie's disease outside the U.S. The XIAFLEX research and development pipeline includes several additional promising indications. BioSpecifics is managing the development of XIAFLEX for uterine fibroids and is conducting a Phase 1 clinical trial. For more information, please visit www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.